Heidelberg, 27 January, 2009 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) was informed of the final result of the mandatory offer made to all SYGNIS shareholders by dievini Hopp BioTech. During the course of the offer, which terminated on January 20, 2009, a total of 3,609,129 shares were tendered at a price of 1.44 Euro. This represents 8.75 % of the issued share capital (41,258,643 euros) and voting rights of SYGNIS Pharma AG.
Consequently, the stake of dievini Hopp BioTech in SYGNIS Pharma AG increased to a total of 18,526,822 shares and approximately 44.90% of the total share capital respectively. dievini Hopp BioTech thus remains the largest shareholder of SYGNIS Pharma AG, followed by BASF SE with 13.49%, Bayer AG with 3.39% and Dr. Frie-drich von Bohlen und Halbach with 5.10%. Accordingly the free float of SYNGIS Pharma AG is 32.96% of the issued share capital.